Eosinophilic esophagitis is an immune-mediated, chronic, inflammatory disease of the esophagus that was first recognized as a distinct entity less than three decades ago.1 The immunopathogenesis of the disease is characterized by type 2 helper T (Th2)–cell inflammation involving T cells, eosinophils, mast cells, and the cytokines interleukin-4, interleukin-5, interleukin-13, and thymic stromal lymphopoietin.2 These cells and mediators are potential targets for antiinflammatory medications. The prevalence of eosinophilic esophagitis has increased rapidly. In Western countries, the disease currently affects approximately 1 in 3000 persons.3 The most common symptom of eosinophilic esophagitis in adults is dysphagia with solid food intake, often . . .